• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TOLTERODINE Drug Record

  • Summary
  • Interactions
  • Claims
  • TOLTERODINE chembl:CHEMBL1382 Approved

    Alternate Names:

    MARIOSEA XL
    KABI-2234
    DETRUSITOL XL
    DETRUSITOL
    NEDITOL XL
    EFFLOSOMYL XL
    BLERONE XL
    INCONEX XL
    PREBLACON XL
    SANTIZOR XL
    TOLTERODINE
    TOLTERODINUM
    (+)-TOLTERODINE
    DETRUSITOL®
    TOLTERODINA
    DETROL®
    (+)-(R)-2-(ALPHA-(2-(DIISOPROPYLAMINO)ETHYL)BENZYL)-P-CRESOL
    chemidplus:124937-51-5
    pubchem.compound:443879
    rxcui:119565
    drugbank:01036
    chembl:CHEMBL1382

    Drug Info:

    Drug Class small molecule
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of incontinence
    Year of Approval 1998
    Drug Class antispasmodics
    Drug Class anti-incontinence agents
    (2 More Sources)

    Publications:

    Maruyama et al., 2006, Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder., J. Urol.
    McNamara et al., 2009, Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist., Eur. J. Pharmacol.
    Sellers et al., 2000, M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro., J Auton Pharmacol
    Nelson et al., 2006, Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor., J. Pharmacol. Exp. Ther.
    Schneider et al., 2004, Signal transduction underlying carbachol-induced contraction of human urinary bladder., J. Pharmacol. Exp. Ther.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Brynne N et al., 1998, Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine., Clin Pharmacol Ther
    Wang H et al., 2017, Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro., Chem Biol Interact
    Malhotra B et al., 2011, Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers., Br J Clin Pharmacol
    Oishi M et al., 2010, Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics., Drug Metab Dispos
    Brynne N et al., 1999, Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance., Br J Clin Pharmacol
    Brynne N et al., 1999, Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole., Br J Clin Pharmacol
  • TOLTERODINE   CHRM2

    Interaction Score: 0.73

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name THVD-201
    Novel drug target Established target
    Trial Name tolterodine extended release capsules,Detrol LA

    PMIDs:
    19168050 11193006 16188951 14769832


    Sources:
    TdgClinicalTrial TEND

  • TOLTERODINE   CHRM3

    Interaction Score: 0.62

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name THVD-201
    Novel drug target Established target
    Trial Name tolterodine extended release capsules,Detrol LA

    PMIDs:
    19168050 11193006 11752352 14769832


    Sources:
    TdgClinicalTrial TEND TTD

  • TOLTERODINE   CHRM4

    Interaction Score: 0.56

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name THVD-201
    Novel drug target Established target
    Trial Name tolterodine extended release capsules,Detrol LA

    PMIDs:
    16406943


    Sources:
    TdgClinicalTrial

  • TOLTERODINE   CHRM1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name THVD-201
    Novel drug target Established target
    Trial Name tolterodine extended release capsules,Detrol LA

    PMIDs:
    17016423 17139284 14769832


    Sources:
    TdgClinicalTrial TEND

  • TOLTERODINE   CHRM5

    Interaction Score: 0.3

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name tolterodine extended release capsules,Detrol LA
    Novel drug target Established target
    Trial Name THVD-201

    PMIDs:
    16406943


    Sources:
    TdgClinicalTrial

  • TOLTERODINE   CYP2D6

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9630826 28087463 21352267 20530222 10583026 10190648


    Sources:
    PharmGKB FDA

  • TOLTERODINE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TOLTERODINE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TOLTERODINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TOLTERODINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TdgClinicalTrial: TOLTERODINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of incontinence
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • TEND: TOLTERODINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class anti-incontinence agents
    Drug Class antispasmodics
    Year of Approval 1998

    Publications:

  • PharmGKB: tolterodine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Malhotra B et al., 2011, Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers., Br J Clin Pharmacol
    Oishi M et al., 2010, Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics., Drug Metab Dispos
    Brynne N et al., 1999, Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole., Br J Clin Pharmacol

  • TTD: Tolterodine

    • Version: 2020.06.01

    Alternate Names:
    D0BZ7W TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1382

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Tolterodine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21